Skip to content

The Actual News

Stay informed without the news wearing you out.

Massive hope for pancreatic cancer pill after trial saw tumours vanish

Massive hope for pancreatic cancer pill after trial saw tumours vanish

Summary

Daraxonrasib, a daily pill given with chemotherapy, showed promising results in an early trial involving 61 people with advanced pancreatic cancer. Tumours stopped growing in 90% of participants, and scans showed no detectable cancer in about 8%; researchers say longer studies are needed to learn whether the treatment extends survival or keeps cancer from returning.

Key Facts

  • The trial included 61 patients whose pancreatic cancer had spread to other parts of the body.
  • Researchers followed patients for an average of about 18 months.
  • Tumours shrank or disappeared in just over 60% of participants.
  • Cancer became undetectable on CT scans in about 8% of participants.
  • Daraxonrasib is a KRAS inhibitor, a drug that blocks certain mutations that can drive tumour growth.
  • The treatment was given alongside chemotherapy.
  • Researchers said longer trials are needed to measure survival and determine how long cancer control lasts.
  • Cancer Research UK reports about 11,500 pancreatic cancer diagnoses and 10,200 deaths each year in Britain.
Read the Full Article

This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.

The week's biggest stories, one calm email every Monday.